DARE News and Press, Dare Bioscience Inc. From 11/10/22

September 30, 2022: $40.4 million in cash and cash equivalents Ovaprene ® : IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to further position the study as the single pivotal study for marketing approval ...

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Stifel 2022 Healthcare Conference, being held...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 10, 2022, to review its financial r...

Approximately 160 to 170 Subjects in Total Are Expected to Complete the Clinical Study; Approximately 100 Subjects Have Completed All Study Assessments to Date Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If Clinical Development is Successful, Sildenaf...

Daré Bioscience ( NASDAQ: DARE ) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with men...

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Oct. 17, 202...

Daré Bioscience ( NASDAQ: DARE ) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive...

SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application allowing Daré to condu...

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences. To learn mor...

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a fireside chat during the H.C. Wainwright 2...